Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
$24.84
-$0.86(-2.67%)
At close: 4:00 PM EST
$24.84
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume108.23K
Average Volume (3M)410.79K
Market Cap
$738.52M
Enterprise Value$658.71M
Total Cash (Recent Filing)$299.50M
Total Debt (Recent Filing)$36.91M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
May 11, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding29,731,197
10 Day Avg. Volume301,435
30 Day Avg. Volume410,792
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit2.79
Enterprise Value/Ebitda50.15
Forecast
1Y Price Target
$48.60Price Target Upside95.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$345.63M
Bulls Say, Bears Say
Bulls Say
Product Adoption - TissueCypherTissueCypher's rapid adoption, marked by a substantial increase in new ordering clinicians and a large remaining market opportunity, positions it as a core revenue driver that can help offset other revenue pressures.
Revenue GuidanceCompany-initiated revenue guidance above analyst consensus signals management confidence in future sales and supports analyst upgrades.
Test Volume - MelanomaHigher-than-expected volumes for the melanoma test and positive physician feedback after guideline updates suggest retention or expansion of ordering physicians, strengthening dermatology revenue prospects.
Bears Say
Commercialization Strategy - AdvanceAD-TxAdjustment of the AdvanceAD-Tx commercialization approach due to limited adoption indicates slower uptake risk and potential delays in realizing forecasted sales.
Discontinued Product HeadwindDiscontinuation of a previously offered test reduced revenue and introduces an ongoing headwind as remaining products must compensate for the lost sales.
Medicare Reimbursement UncertaintyRemoval of Medicare coverage for the SCC skin-cancer test and a pending reconsideration create material reimbursement uncertainty that could limit revenue recovery if coverage is not restored.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $738.52M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is May 11, 2026 which is in 38 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Feb 26, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.259 by $0.179.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.49.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,731,197 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.259. Following the earnings report the stock price went down -7.246%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.60 (95.65% Upside)
$48.60 (95.65% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 10.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $210.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.64%
12-Months-Change
Fundamentals
Return on Equity
-5.27%
Trailing 12-Months
Asset Growth
9.98%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong commercial momentum across core franchises with notable volume growth (105K total test reports, +37%; TissueCypher +86%) and promising early uptake of new products (AdvanceAD-Tx ~500 orders in initial period). The company has a healthy cash balance (~$299.5M) and generated positive free cash flow in 2025. However, profitability and margin metrics deteriorated materially year-over-year (full year net loss $24.2M, adjusted EBITDA down to $44M from $75M, gross margin compressed to 69.2%), driven by lost DecisionDx-SCC revenue, a one-time amortization charge and higher operating expenses. Additional near-term risks include guideline and reimbursement uncertainties and timing for FDA clearance and reimbursement for new tests. Overall the operational growth story and cash strength balance against weakened profitability and reimbursement/timing risks.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$48.60
▲(95.65% Upside)
Technical Analysis
Ownership Overview
2.59% Insiders
24.32% Mutual Funds
29.56% Other Institutional Investors
29.69% Public Companies and
Individual Investors